SCHEMBL599351

SCHEMBL599351

O=C1N=NC(Cl)c2ccccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S100A4 P26447 3/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
POLB P06746 2/20 0.40
ALDH1A1 P00352 3/20 0.36
ALOX15 P16050 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
KDM4E B2RXH2 3/20 0.33
IDO1 P14902 1/20 0.32
DNMT1 P26358 1/20 0.32
DNMT3L Q9UJW3 1/20 0.32
DNMT3A Q9Y6K1 1/20 0.32
CDC25B P30305 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
HPGD P15428 1/20 0.32
TSHR P16473 1/20 0.32
HSD17B10 Q99714 1/20 0.32
TNKS2 Q9H2K2 1/20 0.32
EDNRB P24530 1/20 0.32
EDNRA P25101 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulfuric Acid SCHEMBL3440649 0.90 MEN1 (0.33) S100A4MEN1KMT2APOLBALDH1A1
SCHEMBL9617399 0.76 MEN1 (0.40) S100A4MEN1KMT2APOLBALDH1A1
SCHEMBL11411069 0.76 POLB (0.40) MEN1KMT2APOLBALDH1A1ALOX15
SCHEMBL4060635 0.76 MEN1 (0.40) S100A4MEN1KMT2APOLBALDH1A1
SCHEMBL1032657 0.76 KMT2A (0.40) MEN1KMT2APOLBALDH1A1ALOX15
SCHEMBL16012917 0.76 MEN1 (0.40) S100A4MEN1KMT2APOLBALDH1A1
SCHEMBL11052520 0.76 POLB (0.40) S100A4MEN1KMT2APOLBALDH1A1
SCHEMBL6314591 0.76 MEN1 (0.40) MEN1KMT2APOLBALDH1A1ALOX15
SCHEMBL7892212 0.74 ALDH1A1 (0.41) MEN1KMT2APOLBALDH1A1KDM4E
SCHEMBL10670754 0.73 MEN1 (0.38) MEN1KMT2APOLBALDH1A1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4207112-A STORAGE STABILITY FUJI PHOTO FILM CO., LTD. (JP) 1980-06-10 US claimed
US-10889576-B2 Phthalazinone compounds and methods for the treatment of cystic fibrosis FLATLEY DISCOVERY LAB, LLC (US) 2021-01-12 US disclosed
US-20190256505-A1 PHTHALAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS FLATLEY DISCOVERY LAB LLC (US) 2019-08-22 US disclosed
US-10370366-B2 Pyridazinone compounds and methods for the treatment of cystic fibrosis FLATLEY DISCOVERY LAB, LLC (US) 2019-08-06 US disclosed
US-10280160-B2 Phthalazinone compounds and methods for the treatment of cystic fibrosis FLATLEY DISCOVERY LAB, LLC (US) 2019-05-07 US disclosed
CN-109384727-A Phthalazines ketone compounds, preparation method, pharmaceutical composition and purposes 中国科学院上海药物研究所 2019-02-26 CN disclosed
US-20180093976-A1 PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS FLATLEY DISCOVERY LAB LLC (US) 2018-04-05 US disclosed
US-20180044330-A1 PHTHALAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS FLATLEY DISCOVERY LAB LLC (US) 2018-02-15 US disclosed
US-9783529-B2 Pyridazinone compounds and methods for the treatment of cystic fibrosis FLATLEY DISCOVERY LAB, LLC (US) 2017-10-10 US disclosed
US-9682969-B2 Phthalazinone compounds and methods for the treatment of cystic fibrosis FLATLEY DISCOVERY LAB, LLC (US) 2017-06-20 US disclosed
US-20120040983-A1 Phthalazine Compounds as P38 Map Kinase Modulators and Methods of Use Thereof AMGEN INC. (US) 2012-02-16 US disclosed
WO-2010042649-A2 PHTHALAZINE COMPOUNDS AS p38 MAP KINASE MODULATORS AND METHODS OF USE THEREOF AMGEN INC. (US) 2010-04-15 WO disclosed
WO-2010042646-A1 AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AS P38 MAP KINASE MODULATORS AND METHODS OF USE THEREOF AMGEN INC. (US) 2010-04-15 WO disclosed
EP-0746799-A1 PHOTOTHERMOGRAPHIC ELEMENT WITH CORE-SHELL-TYPE SILVER HALIDE GRAINS Imation Corp (a Delaware Corporation) (US) 1996-12-11 EP disclosed
WO-1995022785-A1 PHOTOTHERMOGRAPHIC ELEMENT WITH CORE-SHELL-TYPE SILVER HALIDE GRAINS MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1995-08-24 WO disclosed
US-4237215-A DECOMPOSING N-HALO COMPOUND IN PRESENCE OF ORGANIC SILVER SALT TO PRODUCE SILVER HALIDE FUJI PHOTO FILM CO., LTD. (JP) 1980-12-02 US disclosed
US-4207112-A STORAGE STABILITY FUJI PHOTO FILM CO., LTD. (JP) 1980-06-10 US disclosed
US-4144072-A CONTAINING A PHTHALAZINONE AND A PHTHALIMIDE FUJI PHOTO FILM CO., LTD. (JP) 1979-03-13 US disclosed
US-4125403-A ORGANIC SILVER SALT, SILVER HALIDE, REDUCING AGENT, PHTHALAZINONE, AND A BENZOXAZINEDIONE OR QUINAZOLINEDIONE FUJI PHOTO FILM CO., LTD. 1978-11-14 US disclosed
US-4076534-A Heat developable light-sensitive material FUJI PHOTO FILM CO., LTD. (JA) 1978-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180044330-A1 PHTHALAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS CFTR, SLC26A4, PKD2 S100A4 4458/4885MEN1 3019/4885KMT2A 3259/4885
US-10889576-B2 Phthalazinone compounds and methods for the treatment of cystic fibrosis CFTR, SLC26A4, PKD2 S100A4 4458/4885MEN1 3019/4885KMT2A 3259/4885
US-10280160-B2 Phthalazinone compounds and methods for the treatment of cystic fibrosis CFTR, SLC26A4, PKD2 S100A4 4458/4885MEN1 3019/4885KMT2A 3259/4885
US-20180093976-A1 PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS CFTR, SLC26A4, PNPO S100A4 3432/4885MEN1 3222/4885KMT2A 3934/4885
US-20120040983-A1 Phthalazine Compounds as P38 Map Kinase Modulators and Methods of Use Thereof MAPK1, MAPK4, MAPK12 S100A4 1014/4885MEN1 4582/4885KMT2A 2665/4885
US-10370366-B2 Pyridazinone compounds and methods for the treatment of cystic fibrosis CFTR, SLC26A4, PNPO S100A4 3432/4885MEN1 3222/4885KMT2A 3934/4885
US-20190256505-A1 PHTHALAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS CFTR, SLC26A4, PKD2 S100A4 4458/4885MEN1 3019/4885KMT2A 3259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.